Showing 76–82 of 82 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Subhashree Barik, Pulak Pritam, Ayon Chakraborty, Sreelipta Das, Sakshi Priyadarsini Dutta, et al.
…x3b1;-crystallin domain., the etiological agent that causes tuberculosis (TB), harbors two α-crystallin-related (Acr) small heat shock proteins, Acr1 (Hsp16.3) and Acr2 (HrpA). Both of these proteins have been reported as crucial for the survival and pathogenesis ofinside t…
Hannah Jarvis, Onn Min Kon
…m-negative, rod-shaped bacilli comprising the Mycobacterium tuberculosis complex (TB) and non-tuberculous mycobacteria. Infection, usually via inhalation, is often asymptomatic but can lead to primary TB or to latent TB infection which can later develop into ‘reactivation’ or ‘po…
Catherine Keiko Gunawan, Anton Sumarpo, Agnes Rengga Indrati
…isease progression and non-AIDS comorbidities, most notably tuberculosis (TB). With rising HIV prevalence, the incidence of HIV-TB co-infection continues to rise, highlighting the need to understand their immunopathological interplay. This narrative review aims to examine the ass…
Javier P Gisbert, María Chaparro
…matologic manifestations. Pretreatment screening for latent tuberculosis is advised. JAK inhibitors cause reversible, dose-dependent cholesterol increases without consistent evidence of a clear impact on cardiovascular risk, but monitoring is advised. Use in pregnancy is discoura…
Abraham Chorbajian, Ira Glassman, Akhila Swarna, Manvita Mareboina, Po-En Chen, et al.
…thritis therapies, especially TNF-α inhibitors, raise tuberculosis (TB) and non-tuberculous mycobacteria (NTM) risk. Type 1 diabetes features impaired cell-mediated immunity and macrophage dysfunction, with evidence forsubspecies(MAP) mimicry involving HSP65-GAD65. In syste…
Laura Mateu-Arrom, Lluis Puig
… inhibitors are associated with an increased risk of latent tuberculosis (LTBI) and hepatitis B virus reactivation. However, not all biologics exert the same immunosuppressive effect, as IL-17 and IL-23 inhibitors may be associated with a lower risk of infection. In general, pre-…
Bijan J. Ghassemieh, Masahiro Narita
An estimated one-quarter of the world population has latent TB infection (LTBI) and 5–10% of those will develop TB disease during their lifetime. Treatment of LTBI can decrease the risk of developing TB disease by 60–90%. Historically, daily isoniazid (INH) for 6–9 months was com…